Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

Core Insights - Dianthus Therapeutics is advancing its investigational monoclonal antibody, claseprubart (DNTH103), targeting severe autoimmune diseases with significant market potential, particularly in generalized Myasthenia Gravis (gMG) [3][4][11] - The company anticipates key clinical trial results for claseprubart, including Phase 2 results from the MaGic trial in gMG in September 2025, and interim analysis from the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 2026 [1][5][6] - Financially, Dianthus reported a net loss of $31.6 million for Q2 2025, with R&D expenses increasing to $26.3 million, reflecting higher clinical costs and increased headcount [13][19] Clinical Development - The Phase 2 MaGic trial for claseprubart in gMG has completed enrollment with 65 patients, exceeding the target of 60, and results are expected in September 2025 [5] - The ongoing Phase 3 CAPTIVATE trial for CIDP is a two-part, randomized withdrawal study, with interim responder analysis anticipated in the second half of 2026 [6] - The Phase 2 MoMeNtum trial for claseprubart in Multifocal Motor Neuropathy (MMN) is also ongoing, with top-line results expected in the second half of 2026 [1][7] Financial Overview - As of June 30, 2025, the company reported $309.1 million in cash, providing a financial runway into the second half of 2027 [1][13] - R&D expenses for Q2 2025 were $26.3 million, up from $18.1 million in Q2 2024, driven by increased clinical and manufacturing costs [13][19] - General and administrative expenses rose to $8.9 million in Q2 2025, compared to $6.0 million in the same period of 2024, primarily due to increased headcount [13][19]